|
Treatment
|
PRNT50a
|
Survival rate (%)
|
|---|
|
Prime
|
1stboost
|
2ndboost
|
|---|
|
rMVA-mep
|
105TCID50
|
<5
|
<8
|
20±1.33
|
60c
|
|
106 TCID50
|
<7
|
9±1.33
|
33±2.33*
|
85c
|
|
107 TCID50
|
<8
|
18±2.33*
|
56±1.01**
|
100c
|
|
Inactivated JEV vaccine
|
9±1.33*
|
29±1.02**
|
58±2.01**
|
100c
|
|
EDIII
|
8±2.00*
|
28±1.99**
|
56±1.99**
|
100c
|
|
rMEP
|
9±1.01*
|
27±2.01**
|
57±1.99**
|
100c
|
|
Wild MVAb
|
--
|
--
|
--
|
0
|
|
PBSb
|
--
|
--
|
--
|
8.33
|
- a Prime-boost-boost vaccinations (days 0, 14 and 28) with rMVA-mep were carried out. On day 14 (prime), day 28 (first boost) and day 42 (second boost) sera were taken and analyzed. 50% plaque reduction neutralizing titer (PRNT50) was shown as the geometrical reciprocal of the sera dilution resulting in a 50% reduction.
- b No JEV-neutralizing antibodies were detectable in 1:2 diluted sera of the mice in the PBS and wild MVA groups. n = 12, values represent the mean ± standard error. Standard group is rMVA/M (105 TCID50).
- * Significance [p< 0.05 to animals immunized with rMVA/M (105TCID50)].
- **Significance [p<0.01 to animals immunized with rMVA/M (105TCID50)].
- c Significance (p< 0.05 to 8.33%).
